CyPath® 肺部检测在新研究中展示了临床实用性

summarizeSummary

bioAffinity Technologies announced a new clinical case study validating its CyPath® Lung diagnostic test. The study highlights the test's ability to support clinical decision-making for high-risk patients with pulmonary nodules, potentially reducing anxiety and unnecessary invasive procedures. This positive clinical validation reinforces the product's value proposition and builds on recent positive developments, including increased revenue for CyPath® Lung and new expert appointments.

check_boxKey Events

• Clinical Case Study Released

  The company issued a press release detailing a new clinical case study for its CyPath® Lung noninvasive diagnostic test.

• 展示临床实用性

  The case study showed CyPath® Lung supported clinical decision-making for a high-risk patient with multiple pulmonary nodules, providing confidence for continued surveillance rather than immediate invasive procedures.

• 减少患者焦虑

  该负性CyPath®肺部检测结果帮助医生和患者更加信心满满，符合肺-RADS 3的建议，建议进行六个月的CT监测计划。

• 强化产品价值

  本次验证突出了检测肺癌在小结节中的92%灵敏度、87%特异度和88%准确率，支持非侵入性管理不确定性肺结节。

auto_awesomeAnalysis

bioAffinity Technologies announced a new clinical case study validating its CyPath® Lung diagnostic test. The study highlights the test's ability to support clinical decision-making for high-risk patients with pulmonary nodules, potentially reducing anxiety and unnecessary invasive procedures. This positive clinical validation reinforces the product's value proposition and builds on recent positive developments, including increased revenue for CyPath® Lung and new expert appointments.